StemCells Inc. (Nasdaq: STEM) will present interim data from a Phase I/II clinical trial in chronic spinal cord injury at the 51st Annual Scientific Meeting of the International Spinal Cord Society on September 3, 2012. The stock price surged 35 cents to close at $1.96.